News
Phase 3 lung cancer fail dents prospects of Ipsen, Servier's...
Ipsen and Servier's hopes of extending the uses for chemotherapy drug Onivyde have been knocked back by a failed phase 3 trial of the drug as a second-line therapy for small cell lung cance
